Literature DB >> 17547859

Treatment of Perianal Fistula and Abscess: Crohn's and Non-Crohn's.

Houssam E Mardini1, David A Schwartz.   

Abstract

The management of perianal abscesses and fistulas is relatively straightforward in most cases and based on a sound knowledge of the anatomy of the anorectum and adherence to established medical and surgical principles. Asymptomatic fistulas should not be treated, whereas abscesses require surgical drainage under general anesthesia. Fistula treatment includes drainage of any associated sepsis and eradication of the fistula track to prevent recurrence while preserving sphincter integrity. A small percentage of anal abscesses and fistulas are complex and very challenging to manage, particularly in conditions such as rectovaginal fistulas and abscesses and/or fistulas complicating Crohn's disease. Treatment strategies in these situations rely on an accurate clinical assessment of the degree of rectal inflammation and perianal pathology. Treatment should combine aggressive medical therapy (antibiotics, immunomodulators, and anti-tumor necrosis factor antibody treatment) and minimal surgical interventions. Patients with proctitis have a significantly lower healing rate and a significantly higher complication rate with aggressive surgical interventions.

Entities:  

Year:  2007        PMID: 17547859     DOI: 10.1007/s11938-007-0014-2

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  38 in total

1.  The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota.

Authors:  David A Schwartz; Edward V Loftus; William J Tremaine; Remo Panaccione; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

2.  Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors:  D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal:  N Engl J Med       Date:  1999-05-06       Impact factor: 91.245

Review 3.  Economic implications of biological therapies for Crohn's disease: review of infliximab.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Management of perianal Crohn's disease.

Authors:  Paul E Wise; David A Schwartz
Journal:  Clin Gastroenterol Hepatol       Date:  2006-04       Impact factor: 11.382

5.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

6.  Efficacy of anal fistula plug in closure of cryptoglandular fistulas: long-term follow-up.

Authors:  Bradley J Champagne; Lynn M O'Connor; Martha Ferguson; Guy R Orangio; Marion E Schertzer; David N Armstrong
Journal:  Dis Colon Rectum       Date:  2006-12       Impact factor: 4.585

7.  Risks and benefits of infliximab for the treatment of Crohn's disease.

Authors:  Corey A Siegel; Chin Hur; Joshua R Korzenik; G Scott Gazelle; Bruce E Sands
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-14       Impact factor: 11.382

8.  Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.

Authors:  William J Sandborn; Daniel H Present; Kim L Isaacs; Douglas C Wolf; Eugene Greenberg; Stephen B Hanauer; Brian G Feagan; Lloyd Mayer; Therese Johnson; Joseph Galanko; Christopher Martin; Robert S Sandler
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

9.  Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement.

Authors:  Miguel Regueiro; Houssam Mardini
Journal:  Inflamm Bowel Dis       Date:  2003-03       Impact factor: 5.325

10.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.